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We report herein an elderly Japanese patient who developed
meningeal and pulmonary cryptococcosis asymptomatically during
the course of prednisolone therapy for bullous pemphigoid (BP)
with a maintenance dosage of 4 mg/d.
A 90-year-old Japanese woman presented with a 1-month his-
tory of itchy erythema. On physical examination, multiple edema-
tous erythema and erythematous papules were seen on her
breasts, abdomen, lower back, and right upper arm. There was a
ﬁrm blister, 20mm in size, on her lower abdomen. Her past medical
history was signiﬁcant for hypertension and chronic renal failure. A
BP180NC16A enzyme-linked immunosorbent assay test was posi-
tive, with a value of 44 U/mL (cutoff 9 U/mL). A whole-body
computed tomography (CT) scan ruled out paraneoplastic pemphi-
goid. We diagnosed her with BP and prednisolone monotherapy,
administered at an initial dosage of 15 mg/d with a gradual
tapering, led to complete disappearance of eruptions.
Seven months after the administration of prednisolone, she was
admitted to our hospital with high fever caused by emphysematous
cystitis. At the time, she had been treated for BP with oral prednis-
olone at 4 mg/d for 2 months. Her laboratory values showed the
following: elevated white blood cell count of 9200/mm3 (range:
4000e8000/mm3), mild anemia [hemoglobinwas 11.0 g/dL (range:
12.0e15.0 g/dL), hematocrit 31.4 % (range: 37.0e45.0 %)], normal
platelets 33 104/mm3 (range: 16e36 104/mm3 ), C-reactive
protein< 0.1 mg/dL (range: <0.299 mg/dL), beta-D-
glucan< 6.0 pg/mL (range: < 6.0 pg/mL), blood urea nitrogen
21 mg/dL (range: 7e30 mg/dL), and an elevated creatinine level
of 1.61 mg/dL (range: 0.4e0.8 mg/dL). The urine Gram stain visual-
ized gram-negative bacteria and Escherichia coliwas detected using
urine culture. A chest x-ray on admission revealed a faint nodule in
the right lung ﬁeld (Figure 1). Intravenous ceftriaxonewas initiated,
and her fever resolved, however, the nodule seen in the chest x-ray
did not regress. CT revealed a round and cavitary nodule, 1 cm in
diameter, in the right lung ﬁeld (Figure 2). Etiologically, pulmonary
cavitary disease in immunocompromised patients is associated
with fungal infections such as Aspergillus, Coccidioides, and Crypto-
coccus.1 Therefore, the lung nodule, which had not been detected in
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positive serum cryptococcal antigenwas identiﬁed. A lumbar punc-
ture showed a cryptococcal antigen with a titer of 1:64 in the cere-
brospinal ﬂuid, and Cryptococcus neoformans was conﬁrmed with
culture of the ﬂuid using the BD Phoenix system (Becton, Dickinson
Diagnostics, Sparks, MD, USA). The patient did not develop head-
ache, personality changes, or symptoms suspicious of central ner-
vous system involvement. Given her age and impaired renal
function, oral ﬂuconazolewas administered. Oral steroid wasmain-
tained and BP did not ﬂare up during hospitalization. C. neoformans
was negative in the cerebrospinal ﬂuid culture 3 months after
discharge and the lung nodule decreased in size as shown in the CT.
Cryptococcosis is an invasive fungal infection causing substan-
tial morbidity andmortality among immunocompromised patients,
including individuals positive for human immunodeﬁciency virus
and those receiving chronic glucocorticoid treatment.2 It is com-
mon for dermatologists to use low-dose corticosteroids for BP ther-
apy; however, there has been only one report of cryptococcosisFigure 1 A chest x-ray on admission showed a faint nodule in the right lung ﬁeld
(black arrow).
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Figure 2 Computed tomography of the lung revealed a round and cavitary nodule,
1 cm in diameter, in the right ﬁeld (black arrow).
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treated with oral prednisolone at 17.5 mg/d for 1 year when she
was diagnosed with cutaneous and pulmonary cryptococcosis.
Our patient had been treated with prednisolone for 7 months at a
lower dosage (15 mg/d), with a gradual tapering to 4 mg/d; howev-
er, she asymptomatically developed cryptococcal meningitis, which
the previous patient did not, and her clinical course would be crit-
ical if we had missed the meningitis. How could we have found her
asymptomatic cryptococcal infection? A chest x-ray on admission
for cystitis showed a faint nodule in the right lung ﬁeld. We had
not performed chest x-rays because the corticosteroid dose hadbeen low and she had never complained of any respiratory symp-
toms. A chest x-ray might have led to early detection of her fungal
infection. Our case demonstrated that even low-dose systemic
prednisolone can cause asymptomatic cryptococcosis. In addition,
a chest x-ray and serum cryptococcal antigen testing4might be use-
ful as a screening tool for cryptococcosis, especially in asymptom-
atic cases like ours.
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